- Trials with a EudraCT protocol (186)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
186 result(s) found for: Implant failure.
Displaying page 2 of 10.
EudraCT Number: 2004-001922-26 | Sponsor Protocol Number: BMI-EU-02-008 | Start Date*: 2006-01-06 |
Sponsor Name:Bioheart, Inc | ||
Full Title: A Phase II, Open-label, Randomized, Multicenter Study to Assess the Safety and Cardiovascular Effects of MyoCell™ Implantation by a Catheter Delivery System in Congestive Heart Failure Patients Pos... | ||
Medical condition: Patients with congestive heart failure who have had a previous myocardial infarction. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (Completed) BE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2022-000066-18 | Sponsor Protocol Number: S65935 | Start Date*: 2022-03-23 |
Sponsor Name:Universitaire Ziekenhuizen Leuven | ||
Full Title: Metastasis-directed therapy for oligorecurrent prostate cancer: a randomized phase III trial | ||
Medical condition: Oligorecurrent hormone-sensitive prostate cancer patients | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: BE (Trial now transitioned) | ||
Trial results: (No results available) |
EudraCT Number: 2010-021434-55 | Sponsor Protocol Number: FE 200486 CS35A | Start Date*: 2010-11-11 | |||||||||||
Sponsor Name:Ferring Pharmaceuticals A/S | |||||||||||||
Full Title: An Open-label, Multi-Centre, Extension Trial, Evaluating the Long-Term Progression-Free Survival of Degarelix or Goserelin Three-Month Dosing Regimens in Patients with Prostate Cancer Requiring And... | |||||||||||||
Medical condition: Prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: HU (Prematurely Ended) GB (Prematurely Ended) FI (Prematurely Ended) NL (Prematurely Ended) CZ (Completed) BE (Completed) DE (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002228-40 | Sponsor Protocol Number: A3191193 | Start Date*: 2006-08-28 |
Sponsor Name:PFIZER | ||
Full Title: A PHASE III PLACEBO-CONTROLLED TRIAL OF CELECOXIB IN GENOTYPE POSITIVE SUBJECTS WITH FAMILIAL ADENOMATOUS POLYPOSIS | ||
Medical condition: FAMILIAL ADENOMATOUS POLYPOSIS (FAP) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: ES (Prematurely Ended) SE (Completed) IT (Prematurely Ended) GB (Completed) CZ (Prematurely Ended) BE (Prematurely Ended) DE (Completed) HU (Prematurely Ended) SK (Completed) BG (Not Authorised) | ||
Trial results: View results |
EudraCT Number: 2022-000149-34 | Sponsor Protocol Number: CR845-310302 | Start Date*: 2023-01-17 | |||||||||||
Sponsor Name:Cara Therapeutics, Inc. | |||||||||||||
Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled 12-Week Study to Evaluate the Safety and Efficacy of Oral Difelikefalin in Advanced Chronic Kidney Disease Subjects with Moderate-to-Seve... | |||||||||||||
Medical condition: Chronic Kidney Disease | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: HU (Prematurely Ended) ES (Prematurely Ended) IT (Prematurely Ended) PL (Prematurely Ended) BG (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2021-001036-25 | Sponsor Protocol Number: UNI91103-201 | Start Date*: 2021-06-01 | |||||||||||
Sponsor Name:UNION therapeutics A/S | |||||||||||||
Full Title: A RANDOMIZED PLACEBO-CONTROLLED PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UNI91103 INTRANASAL ADMINISTRATION IN ADULTS WITH ASYMPTOMATIC OR MILDLY SYMPTOMATIC COVID-19 | |||||||||||||
Medical condition: Covid-19 | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-003570-26 | Sponsor Protocol Number: CLN-PRO-V011 | Start Date*: 2019-09-07 | ||||||||||||||||
Sponsor Name:Humacyte, Inc. | ||||||||||||||||||
Full Title: A Phase 2 Assessment of Humacyte’s Human Acellular Vessel in Patients Needing Vascular Access for Dialysis | ||||||||||||||||||
Medical condition: End-stage renal disease (ESRD) requiring placement of an arteriovenous (AV) graft in the arm (upper- or forearm) for dialysis access. | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: PL (Prematurely Ended) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2016-002280-34 | Sponsor Protocol Number: 1245.121 | Start Date*: 2017-06-19 | |||||||||||
Sponsor Name:Boehringer Ingelheim International GmbH | |||||||||||||
Full Title: A phase III randomised, double-blind trial to evaluate efficacy and safety of once daily empagliflozin 10 mg compared to placebo, in patients with chronic Heart Failure with reduced Ejection Fracti... | |||||||||||||
Medical condition: Heart failure (HF) with reduced ejection fraction (EF). | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) NL (Completed) FR (Completed) ES (Completed) HU (Completed) CZ (Completed) BE (Completed) GB (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000799-33 | Sponsor Protocol Number: 001 | Start Date*: 2007-06-22 |
Sponsor Name:Universitätsklinikum Essen | ||
Full Title: A Study of the efficacy and safety of Rizatriptan 10 mg PRD in the treatment of acute migraine in patients with non satisfactory response to previous pharmacologic treatment | ||
Medical condition: acute migraine | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002487-41 | Sponsor Protocol Number: GLY-321-2017 | Start Date*: 2018-01-31 | |||||||||||
Sponsor Name:GLyPharma Therapeutic Inc. (a wholly owned subsidiary of VectivBio Holding AG) | |||||||||||||
Full Title: A Phase Ib/IIa open-label, repeated dose, metabolic balance study of FE 203799 in patients with short bowel syndrome | |||||||||||||
Medical condition: Short bowel syndrome (SBS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-000253-21 | Sponsor Protocol Number: 106538 | Start Date*: 2006-04-12 |
Sponsor Name:GlaxoSmithKline GmbH & Co KG | ||
Full Title: Reaching asthma control with salmeterol/fluticasone 50 / 250µg bd combination in steroid naive or low dose JCS patients by using the asthma control test (ACT) as measurement. | ||
Medical condition: Asthma control | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2004-000675-34 | Sponsor Protocol Number: EU 101 | Start Date*: 2004-12-21 |
Sponsor Name:University Medical Center Utrecht | ||
Full Title: A Prospective, Randomized, Controlled, Multi-center, (Pilot) Study of Osigraft® in Instrumented Posterolateral Fusions | ||
Medical condition: Subjects qualifying for decompression and fusion of one spinal level (L3-S1) with the use of autograft will be recruited through the medical institutions of participating investigators. All subject... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2005-005494-29 | Sponsor Protocol Number: 1603 | Start Date*: Information not available in EudraCT |
Sponsor Name:Ullevål University Hospital | ||
Full Title: Rifampin combination therapy versus monotherapy in early staphylococcal infections after total hip and knee arthroplasty | ||
Medical condition: Joint prosthesis infection after total hip and knee arthroplasty. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NO (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2015-001041-83 | Sponsor Protocol Number: FKC-009 | Start Date*: 2015-04-13 | |||||||||||
Sponsor Name:Astellas Pharma Canada Inc. | |||||||||||||
Full Title: Clinical and Laboratory Evaluation of Acute Rejection, Myocyte Growth, Repair, and Oxidative Stress Following de novo Cardiac Transplant: A Comparison between Tacrolimus- and Cyclosporine- based Im... | |||||||||||||
Medical condition: Cardiac transplant recipients | |||||||||||||
|
|||||||||||||
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-020825-42 | Sponsor Protocol Number: RTOG0815 | Start Date*: 2010-11-08 | |||||||||||
Sponsor Name:Radiation Therapy Oncology Group | |||||||||||||
Full Title: A PHASE III PROSPECTIVE RANDOMIZED TRIAL OF DOSE-ESCALATED RADIOTHERAPY WITH OR WITHOUT SHORT-TERM ANDROGEN DEPRIVATION THERAPY FOR PATIENTS WITH INTERMEDIATE-RISK PROSTATE CANCER | |||||||||||||
Medical condition: intermediate risk prostate cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: IE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2010-021719-18 | Sponsor Protocol Number: KS-2009-003 | Start Date*: 2011-12-02 | |||||||||||
Sponsor Name:Hannover Medical School | |||||||||||||
Full Title: Phase I/II study on cytarabine and idarubicine combined with escalating doses of clofarabine as induction therapy in patients with acute myeloid leukemia and high risk for induction failure (CIARA) | |||||||||||||
Medical condition: Patients with acute myeloid leukemia (AML) and high risk for induction failure | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-000471-20 | Sponsor Protocol Number: RIPH_2019_01 | Start Date*: 2020-11-30 | |||||||||||
Sponsor Name:CH Tourcoing | |||||||||||||
Full Title: Rifabutin versus rifampicin for treatment of staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy): a multicenter randomized, open-la... | |||||||||||||
Medical condition: Adult with an staphylococcal prosthetic joint infection treated with debridement, antibiotics and implant retention (DAIR strategy) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-002749-38 | Sponsor Protocol Number: BT0800NED001 | Start Date*: 2007-07-18 |
Sponsor Name:Barrier Therapeutics nv | ||
Full Title: A randomized, double-blind, placebo-controlled exploratory trial to evaluate a one-week oral treatment with R129160 (60 mg o.d.) in patients with chronic idiopathic urticaria | ||
Medical condition: Chronic Idiopathic Urticaria | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BE (Completed) CZ (Completed) NL (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2017-002486-21 | Sponsor Protocol Number: GLY-311-2017 | Start Date*: 2018-01-18 | |||||||||||
Sponsor Name:GLyPharma Therapeutic, Inc. (a wholly owned subsidiary of VectivBio Holding AG) | |||||||||||||
Full Title: A once weekly, repeated dose, placebo controlled, double blind, randomised cross-over trial investigating safety, efficacy and pharmacodynamics of FE 203799 in patients with short bowel syndrome wi... | |||||||||||||
Medical condition: Short Bowel Syndrome (SBS) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-000361-78 | Sponsor Protocol Number: HTA-HUR-01 | Start Date*: 2020-12-01 |
Sponsor Name:HOLOSTEM TERAPIE AVANZATE S.R.L. | ||
Full Title: PROSPECTIVE, OPEN-LABEL, UNCONTROLLED CLINICAL TRIAL TO ASSESS THE SAFETY AND EFFICACY OF AUTOLOGOUS CULTURED ORAL MUCOSA GRAFTS FOR URETHRAL RECONSTRUCTION IN PATIENTS DUE TO HYPOSPADIAS TREATMENT... | ||
Medical condition: Urethral reconstruction in patients due to hypospadias treatment failure. | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male | |
Trial protocol: IT (Prematurely Ended) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
